首页> 外文会议>American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics >Quantification assay of imatinib in patient plasma and characterization of its metabolism in human urine and liver microsomes using LC-ESI-MS/MS
【24h】

Quantification assay of imatinib in patient plasma and characterization of its metabolism in human urine and liver microsomes using LC-ESI-MS/MS

机译:使用LC-ESI-MS / MS的患者血浆患者血浆患者血浆和肝微粒体中代谢的表征的定量测定

获取原文

摘要

This sensitive LC-ESI-MS/MS assay of STI and CGP74588 metabolite has been applied successfully to clinical pharmacokinetic studies in adults (4) and children to provide therapeutic drug monitoring for efficient response of treatment and better understanding of individual metabolic variations as shown with different pharmacokinetic plasma concentration-time profiles for two adult patients (Fig 1 and 2). For P26, two-fold lower plasmatic and lower urinary STI and CGP concentrations can be explained by higher urine biotransformation of drug: 80percent (U26) versus 50percent (U30).
机译:STI和CGP74588代谢物的这种敏感的LC-ESI-MS / MS测定已成功应用于成人(4)和儿童的临床药代动力学研究,以提供治疗药物监测,以便有效响应治疗,并更好地了解单个代谢变化,如图所示 两个成年患者的不同药代动力学血浆浓度 - 时间谱(图1和2)。 对于P26,可以通过药物的更高尿液生物转化来解释双重血浆和低尿液STI和CGP浓度:80%(U26)与50%(U30)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号